This company listing is no longer active
Rize Oncology (RIZE) Stock Overview
A biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RIZE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Rize Oncology Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.03 |
| 52 Week High | CA$0.18 |
| 52 Week Low | CA$0.015 |
| Beta | 2.5 |
| 1 Month Change | 0% |
| 3 Month Change | -70.00% |
| 1 Year Change | 20.00% |
| 3 Year Change | -90.63% |
| 5 Year Change | n/a |
| Change since IPO | -95.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| RIZE | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -75.0% | 4.3% | 1.4% |
| 1Y | 20.0% | -51.4% | 19.9% |
Return vs Industry: RIZE exceeded the Canadian Pharmaceuticals industry which returned -57.1% over the past year.
Return vs Market: RIZE exceeded the Canadian Market which returned 12.6% over the past year.
Price Volatility
| RIZE volatility | |
|---|---|
| RIZE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 12.3% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.6% |
Stable Share Price: RIZE's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine RIZE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Roland Boivin | rizeoncology.com |
Rize Oncology Inc. engages in the development of oncology therapeutics. It develops STS-201, a small-molecule drug for the treatment of soft tissue sarcoma. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025.
Rize Oncology Inc. Fundamentals Summary
| RIZE fundamental statistics | |
|---|---|
| Market cap | CA$2.27m |
| Earnings (TTM) | -CA$756.77k |
| Revenue (TTM) | n/a |
Is RIZE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RIZE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$550.92k |
| Earnings | -US$550.92k |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0073 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RIZE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 17:09 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rize Oncology Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.